Abbisko Cayman Limited (HKG:2256)
Hong Kong · Delayed Price · Currency is HKD 9.61
-0.31 (-3.13%)
Jul 30, 2026, 3:38 PM HKT
Abbisko Cayman Revenue
In the year 2025, Abbisko Cayman had annual revenue of 612.12M CNY with 21.45% growth.
Revenue
612.12M CNY
Revenue Growth
+21.45%
P/S Ratio
10.43
Revenue / Employee
2.22M CNY
Employees
276
Market Cap
7.11B HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 612.12M | 108.13M | 21.45% |
| Dec 31, 2024 | 503.99M | 484.93M | 2,544.24% |
| Dec 31, 2023 | 19.06M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 22.68M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Shanghai Haohai Biological Technology | 2.73B |
| Everest Medicines | 1.90B |
| Lepu Biopharma | 1.04B |
| Alphamab Oncology | 630.11M |
| CStone Pharmaceuticals | 299.99M |
| Suzhou Ribo Life Science | 165.26M |
| CARsgen Therapeutics Holdings | 139.84M |
| Shanghai Bao Pharmaceuticals | 54.70M |
Abbisko Cayman News
- 4 weeks ago - Abbisko Therapeutics And AstraZeneca Enter Strategic Collaboration For Lumipodlin - Nasdaq
- 5 weeks ago - Abbisko Therapeutics Collaborates With Eli Lilly For Research And Development; Stock Up - Nasdaq
- 5 weeks ago - Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly - Reuters